Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06377839
Other study ID # N-20230048
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date January 10, 2024
Est. completion date December 1, 2025

Study information

Verified date April 2024
Source Aalborg University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pain is the most common complication following surgical removal of an impacted mandibular third molar. Several risk factors may increase the intensity and duration of pain following removal of mandibular third molars. Acute postoperative pain can transcript into postoperative chronic pain without an explainable reason or a specific risk factor. The use of advanced platelet-rich fibrin in the extraction socket following surgical removal of mandibular third molar have diminished the intensity and duration of acute postoperative pain and facilitated improved wound healing. The objective of the present study is therefore to identified specific risk factors and predictors for developing postoperative chronic pain following surgical removal of mandibular third molars with or without advanced platelet-rich fibrin applied in the extraction socket using epigenetic modulation.


Description:

Pain is the most common complication following surgical removal of an impacted mandibular third molar (SRM3). Acute postoperative pain (APP) following SRM3 is a normal physiological response to the tissue damage and usually treated sufficiently by paracetamol, non-steroidal anti-inflammatory drugs, or opioids. Increasing age, gender, smoking habit, length of surgery, type of anesthesia, intraoperative complications, surgeon's experience, and contamination of the surgical wound are well-known risk factors that affects the intensity and duration of APP. However, APP can transcript into postoperative chronic pain (PCP) without an explainable reason or a specific risk factor. Moreover, specific predictors for development of PCP following SRM3 is currently not sufficiently elucidated. PCP is defined as pain lasting for two months or more after surgery, when other causes of pain are excluded. The characteristics and intensity of PCP varies among individuals and specific factors for developing PCP has not yet been clearly elucidated. PCP leads to severe functional limitations and impaired oral health-related quality of life (OHRQoL). The presence of pain prior to surgery as well as the intensity and duration of APP are considered as critical predictors for developing PCP. Various pharmacological and preventive strategies have therefore been proposed to minimize the risk of APP following SRM3 including modification of the surgical technique, sufficient intra- and postoperative pain control as well as preoperative psychological intervention focusing on the psychosocial and cognitive risk factors. Moreover, risk factors, such as genetic and epigenetic modifications have also been associated with APP and PCP. Among epigenetic modifications, non-coding RNAs have shown to be associated with the development of PCP. However, clarification of factors that specifically influence the development of PCP following SRM3 remains unknown. Advanced platelet-rich fibrin (APRF) is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Manufacturing of APRF from blood samples and application of APRF in the extraction socket following SRM3 have diminished the intensity and duration of APP and facilitated improved wound healing, as reported in systematic reviews and meta-analyses. Application of APRF in the extraction socket following SRM3 possess therefore the ability to minimize the risk of developing PCP due to a shorter period of APP. The objective of the present study is therefore to identified specific predictors for developing PCP following SRM3. Eighty patients with an impacted mandibular third molar will be randomly allocated to SRM3 with or without application of APRF in the extraction socket. A standardized postoperative pain-management regime will be applied following SRM3. Blood samples (80mL) will be obtained intraoperative and one week postoperatively for all included patients. The investigated non-coding RNAs in the blood of participants will be used to assess their association with pain sensitivity and risk of developing PCP. Self-administrated questionnaires and visual analogue scale (VAS) will be used to correlate the results of the of non-coding RNA dysregulation with the duration and intensity of postoperative pain, social and working isolation, physical appearance, eating and speaking ability, diet variations, sleep impairment, and discomfort after one week, one month, and one year, respectively. The Modified Dental Anxiety Scale is used to measure preoperatively dental anxiety. OHRQoL is evaluated by self-administrated questionnaires obtained preoperatively and compared with postoperative assessment after one week, one month, and one year. The primary outcome measure is intensity and duration of postoperative pain following SRM3 with or without application of APRF in the extraction socket. These results will be correlated with alteration in non-coding RNAs expression to identified possible predictors for developing PCP. The results will be published in international peer-reviewed journals as well as presented at congresses.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 1, 2025
Est. primary completion date April 17, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years. - Presence of a semi- or fully impacted mandibular third molar. - Indication for surgical removal of mandibular third molar. Exclusion Criteria: - Patients suffering from chronic pain syndrome. - Patients in need of daily analgetic. - Pregnancy. - Psychiatric problems or unrealistic expectations.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Advanced platelet-rich fibrin in the ekstraction socket
Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.

Locations

Country Name City State
Denmark Department of Oral and Maxillofacial surgery, Aalborg University Hospital Aalborg Nordjylland

Sponsors (2)

Lead Sponsor Collaborator
Aalborg University Hospital Aalborg University

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of postoperative pain by using Visual Analoque scale Measurements of pain using Visual Analogue Scale (0 is no pain and 100 is the worst pain), so lower score is a better outcome Postoperative (15 days)
Secondary Assessment of quality of life Questionnaire for assessment of quality of life Pre- and postoperative (1-year)
See also
  Status Clinical Trial Phase
Completed NCT03793790 - The Role of Learning in Nocebo Hyperalgesia N/A
Completed NCT04527770 - Midazolam Versus Dexamethasone as an Adjuvant to Local Anesthetics in the Ultrasound Guided Hydrodissection of Median Nerve for Treatment of Carpal Tunnel Syndrome Patients N/A
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Withdrawn NCT03707444 - A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer
Recruiting NCT03498976 - RFp on Suprascapular N. Versus RFp on Suprascapular N. and Circumflex in the Treatment of Painful Shoulder N/A
Recruiting NCT04299893 - Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ) Phase 2/Phase 3
Completed NCT04625504 - Investigating Biological Targets, Markers, and Intervention for Chronic Pain N/A
Recruiting NCT06072001 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Phase 3
Recruiting NCT06071988 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Phase 3
Recruiting NCT06072573 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Phase 3
Recruiting NCT06071962 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Phase 3
Recruiting NCT06072560 - Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Phase 3
Recruiting NCT06071936 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Phase 3
Recruiting NCT06071975 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Phase 3
Recruiting NCT06071949 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Phase 3
Completed NCT05811455 - Comparative Effects of Aerobic Exercises and Progressive Muscle Relaxation Exercises on Pain and Quality of Life N/A
Completed NCT03755817 - Efficacy Assessment of SCENAR Device on Common Spinal Pain Syndrome N/A
Completed NCT06010381 - Muscle Energy Technique Versus Maitland Mobilization on Shoulder Pain and Disability N/A
Terminated NCT03421951 - Change in Pain and Quality of Life Following SCS for Chronic Pain
Recruiting NCT05834725 - Resilience Coaching for Adolescents With Chronic Musculoskeletal Pain N/A